Basit öğe kaydını göster

Aggravation of atonic seizures by rufinamide: A case report.

dc.contributor.authorBektas, Gonca
dc.contributor.authorAydinli, Nur
dc.contributor.authorOzmen, Meral
dc.contributor.authorTatli, Burak
dc.contributor.authorAydin, Ali
dc.contributor.authorCaliskan, Mine
dc.contributor.authorYildiz, Edibe
dc.date.accessioned2021-03-04T18:45:26Z
dc.date.available2021-03-04T18:45:26Z
dc.date.issued2016
dc.identifier.citationBektas G., Caliskan M., Aydin A., Yildiz E., Tatli B., Aydinli N., Ozmen M., "Aggravation of atonic seizures by rufinamide: A case report.", Brain & development, cilt.38, ss.654-7, 2016
dc.identifier.issn0387-7604
dc.identifier.otherav_8c5ba591-1822-4711-b8d6-debfa3ebf5b5
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/94958
dc.identifier.urihttps://doi.org/10.1016/j.braindev.2016.02.005
dc.description.abstractBackground: Rufinamide is a novel antiepileptic drug used as adjunctive therapy in patients with Lennox-Gastaut syndrome and provides seizure control especially in tonic and atonic seizures. Rufinamide is expected to be effective in intractable epilepsy when atonic and tonic seizures exist. However, rufinamide induced seizure aggravation has been reported in a few patients, which was not associated with a specific type of seizure.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.titleAggravation of atonic seizures by rufinamide: A case report.
dc.typeMakale
dc.relation.journalBrain & development
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume38
dc.identifier.issue7
dc.identifier.startpage654
dc.identifier.endpage7
dc.contributor.firstauthorID233984


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster